Clinical trials: Pancreatic Insulinoma
Pancreatic Cancer
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth.
- Trial name
- NCT01056601
- Testing
- Bortezomib, Panobinostat
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control symptoms, such as diarrhea, caused by the tumor.
- Trial name
- NCT00227773
- Testing
- octreotide acetate, vatalanib, anti-cytokine therapy
- Sponsor
- Eastern Cooperative Oncology Group
Gastrinoma, Glucagonoma
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma
- Trial name
- NCT01824875
- Testing
- temozolomide, capecitabine
- Where
- 323 sites in United States
- Volunteers
- 144 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Insulinoma; Pancreas, MEN1
Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions
The goal of this observational study is to evaluate the long-term clinical effectiveness of EUS-RFA and quality of life in patients with pancreatic or adrenal tumors recieving EUS-RFA.
- Conditions
- Insulinoma; Pancreas, MEN1, NETs, Radiofrequency Ablation
- Trial name
- EURAGIL (NCT07272187)
- Testing
- observational study
- Where
- Denmark
- Volunteers
- 138 people
- Sponsor
- Herlev Hospital
Insulinoma, Nesidioblastosis
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients.
- Trial name
- NCT02560376
- Testing
- 68Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Insulinoma
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
Glucagon-like peptide-1 receptor (GLP-1R)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect insulinoma, like the widely studied [68Ga]Ga-NOTA-exendin-4.
- Trial name
- NCT05034783
- Testing
- [68Ga]Ga-HBED-CC-exendin-4, [68Ga]Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Endogenous Hyperinsulinaemic Hypoglycaemia
New Imaging Procedure for the Localisation of Insulinoma
Insulinoma: Insulinoma are rare, small insulin secreting neuroendocrine tumors. The only curative approach is the surgical excision. The preoperative detection remains a challenge.
- Trial name
- NCT02127541
- Testing
- Ga -exendin PET/CT, In- exendin SPECT/CT, MRI
- Where
- Switzerland
- Volunteers
- 52 people
- Sponsor
- University Hospital, Basel, Switzerland
Gastrinoma, Glucagonoma
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00075439
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Insulinoma
Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization
This clinical research evaluates a new PET/CT imaging agent, [68Ga]Ga-HBED-CC-PEG6-exendin-4, for localizing insulinoma, a rare pancreatic tumor that causes severe low blood sugar.
- Trial name
- HBED-CC-PEG6-E (NCT07808879)
- Testing
- [68Ga]Ga-HBED-CC-PEG6-exendin-4 PET/CT, [68Ga]Ga-HBED-CC-exendin-4 PET/CT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Insulinoma
EUS-guided Ethanol Ablation of an Insulinoma
The present study aims to evaluate the feasibility, safety and efficacy of EUS-guided ethanol ablation of an insulinoma.
- Trial name
- EUS (NCT02121366)
- Testing
- EUS-guided ethanol ablation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangxi Medical University
Tumor-associated Hyperinsulinism (Tumor HI)
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
This expanded access program is intended to provide ersodetug, an investigational drug, to eligible participants who suffer from inadequately controlled hypoglycemia due to tumor-associated hyperinsulinism and are unable to…
- Trial name
- NCT07262970
- Testing
- Ersodetug (9 mg/kg) + SOC
- Where
- United States
- Sponsor
- Rezolute
Pancreatic Tumor, Benign, Pancreatic Neoplasms
Laser Tissue Welding - Distal Pancreatectomy Sealing Study
The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.
- Conditions
- Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst
- Trial name
- LTW (NCT03147768)
- Testing
- Distal Pancreatectomy Sealing Using LTW
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Laser Tissue Welding, Inc.
Congenital Hyperinsulinism, Insulinoma
Pasireotide in Hyperinsulinemic Hypoglycemia
This is a small controlled pilot study to assess the effect of subcutaneous pasireotide on preventing hypoglycemia due to hyperinsulinism, including congenital hyperinsulinism and insulinoma.
- Conditions
- Congenital Hyperinsulinism, Insulinoma, Hyperinsulinism
- Trial name
- NCT03053284
- Testing
- Pasireotide 0.6Mg Solution for Injection, Saline Solution
- Sponsor
- Montefiore Medical Center
Hypercalcemia, Familial Primary Hyperparathyroidism
Cinacalcet to Treat Familial Primary Hyperparathyroidism
This study will evaluate the benefits and side effects of a new medication called Cinacalcet for treating patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 (MEN1) or type 2A (MEN2A).
- Trial name
- NCT00325104
- Testing
- Parathyroid hormone testing, Serum calcium testing
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Insulinoma; Pancreas
Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies.
- Trial name
- EUSRFAINSU (NCT07585032)
- Testing
- EUS-RFA
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Sahlgrenska University Hospital
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects of treatment and improve the ability to plan treatment for patients with gastrointestinal-related neuroendocrine tumors.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00454376
- Testing
- questionnaire administration, quality-of-life assessment
- Where
- 16 sites in Denmark, Germany and 8 more
- Volunteers
- 408 people
- Sponsor
- National Cancer Institute (NCI)
Insulinoma
A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct
The purpose of this study is to compare the clinical efficacy and economic cost of enucleation after placement of pancreatic duct stents before surgery with that of direct enucleation alone, and to evaluate its safety and…
- Trial name
- NCT05523778
- Testing
- placement of pancreatic duct stents before enucleation surgery, Direct enucleation surgery
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Insulinoma
EUS-RFA Versus Surgery for Pancreatic Insulinoma (ERASIN-RCT)
The goal of this muticentre randomized controlled trial is to compare endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with surgery for treatment of pancreatic insulinoma.
- Trial name
- ERASIN-RCT (NCT05735912)
- Testing
- Endoscopic ultrasound-guided radio frequency ablation, Surgery
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona